Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center. Leukemia 2014 Jun;28(6):1365-8
Date
01/24/2014Pubmed ID
24451411Pubmed Central ID
PMC4047185DOI
10.1038/leu.2014.42Scopus ID
2-s2.0-84902073992 (requires institutional sign-in at Scopus site) 18 CitationsAuthor List
Stephens DM, Ruppert AS, Jones JA, Woyach J, Maddocks K, Jaglowski SM, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Johnson AJ, Muthusamy N, Heerema NA, Byrd JCAuthor
Samantha M. Jaglowski MD, MPH Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdultAged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Chromosome Deletion
Chromosomes, Human, Pair 17
Female
Follow-Up Studies
Humans
In Situ Hybridization, Fluorescence
Karyotyping
Leukemia, Lymphocytic, Chronic, B-Cell
Male
Middle Aged
Molecular Targeted Therapy
Neoplasm Recurrence, Local
Prognosis
Survival Rate